Printer Friendly

Dainippon Sumitomo Pharma Receives Approval for Orally Disintegrating Formulation of Amlodin, Hypertension/Angina Pectoris Treatment.

Tokyo, Japan, Mar 20, 2006 - (JCN) - Dainippon Sumitomo Pharma announced on March 17 that it has received approval for its proprietary ethical drugs, Amlodin OD Tablet 2.5mg/ 5mg, from the Ministry of Health, Labor and Welfare as of March 15.

Produced using the company's proprietary formulation technology SUITAB, the orally disintegrating tablets are a calcium antagonist indicated for the treatment of hypertension and angina pectoris.

The company will put on sale the product after the National Health Insurance listing. Amlodin has been widely prescribed in Japan since its release in 1993.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Mar 21, 2006
Words:102
Previous Article:Fisheries Research Agency Confirms Fermented Seaweed is Effective for Red Sea Bream Iridovirus Infection, Begins Testing Mass Fermentation Technology...
Next Article:Kobayashi Pharmaceutical Sets up New Subsidiary in Germany.


Related Articles
FDA APPROVES BIOVAIL'S GENERIC PROCARDIA XL 30MG DOSAGE.
Onset of action of orally disintegrating olanzapine versus conventional olanzapine.
NOVADEL SELECTS INYX TO PRODUCE NITROGLYCERIN LINGUAL SPRAY.
Sumitomo Chemical Files Suit Against Pfizer for Amlodipine Besilate.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs.
Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'.
Sumitomo Chemical Reports Interim Consolidated Financial Results.
Sumitomo Chemical Reports Consolidated Financial Results For the Nine Months Ended December 31, 2006.
Dainippon Sumitomo Pharma Announces Launch of "Replagal(R) 3.5 mg" for Anderson-Fabry Disease.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters